Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2025 09:15 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
December 30, 2024 16:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing

HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
December 23, 2024 07:55 ET | Source: Fibrobiologics, Inc.

FibroBiologics Announces $25 Million Financing

HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
November 19, 2024 09:15 ET | Source: Fibrobiologics, Inc.

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of...
November 14, 2024 09:15 ET | Source: Fibrobiologics, Inc.

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
November 12, 2024 16:20 ET | Source: Fibrobiologics, Inc.

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the...
October 29, 2024 09:15 ET | Source: Fibrobiologics, Inc.

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
October 28, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
October 18, 2024 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development,...
October 16, 2024 09:15 ET | Source: Fibrobiologics, Inc.

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...